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GPCRThis study involves the structural and functional properties of the recombinant melanocortin 4 receptor
(MC4R) expressed in the HEK-293 cell line. Using co-immuno-puriﬁcation approaches, the receptor appears
to be an oligomer, which can be crosslinked through disulphide bonds involving a native cysteine residue
(84) to give a dimeric species. This position is located near the cytosolic region of transmembrane segment
2 and it is suggested that this is an interacting interface between MC4R monomers. Using co-expression of
the native protein and a C84A mutant, it appears that the receptor also forms higher order oligomers via al-
ternative interfaces. Interestingly, disulphide crosslink formation does not occur if the receptor is uncoupled
from its G-protein, even though the oligomeric state is preserved. This suggests that the conformational
changes, which occur on activation, affect the TM2 interface. The pharmacology of the agonist, NDP-MSH, in-
dicates that the MC4R retains high afﬁnity for the ligand in the absence of the G-protein but occupancy for the
ligand is increased. The data can be interpreted to suggest that the G-protein exerts a negative allosteric effect
on the receptor. Co-expression of one receptor lacking the ability to signal with another, which cannot bind
the agonist, restored ligand-dependent activation of the G-protein to situations in which neither receptor on
its own could activate the G-protein. Such transactivation suggests meaningful cross talk between the recep-
tor subunits in the oligomeric complex. These studies demonstrate further unique features of the MC4R.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The MC4R belongs to Family A of the G-protein coupled receptors
(GPCRs) and is conventionally activated by peptide agonists inducing
coupling to Gαs, although not exclusively [1]. The receptor is located
primarily in the brain and shown to have an important regulatory role
in energy homeostasis and food intake [2–4]. It is, therefore, a poten-
tial therapeutic target for a variety of conditions including anorexia
and obesity [5]. Understanding its functionality may be the key to
successfully exploiting the receptor as a druggable target. MC4R pos-
sesses unique structural features not seen in other Family A members.
These include some highly conserved key residues in TM regions
which have been substituted including; Pro4.59, 5.50 residues at TM4
and TM5 respectively and the Cys3.25 residue located in the extracel-
lular portion of TM3 which generally forms a disulphide bond to a CysAgRP, Agouti-related protein;
P, copper 1–10 phenanthroline;
guanine nucleotide-binding reg-
)p, guanosine-5′-(βγ-imino)tri-
HA epitope, human inﬂuenza
H, [Nle4, D-Phe7] α-MSH; TM,
perial College London, Charing
0178.
man).
rights reserved.residue in ECL2. The Family A conserved Cys3.25 residue is substituted
in the MC4R by Asp3.25 (Asp122) which plays a key role in interacting
with the agonist peptides [6–8]. The atypically small ECL2 lacks the
second conserved Cys residue in the disulphide bond, the Asp189 in
its place also being critical for agonist binding [6–8].
The MC4R endogenous agonists are the melanocortin peptide
which contains a conserved tetrapeptide sequence His-Phe-Arg-Trp-
[9,10] and the pharmacological tool, NDP-MSH, developed from the
endogenous peptide α-MSH, whereby the essential Phe7 in the
tetrapeptide sequence is replaced with D-Phe7 to give an agonist of
increased potency [9,10].
Not only is MC4R structurally disparate from other Family A GPCRs
but the receptor is also unusual in that it also has a native antagonist,
the 132 residue agouti related protein (AgRP) which is expressed in
the neurones of the arcuate nucleus of the hypothalamus [11]. It has
been shown to lower constitutive levels of cAMP [12–14].
It is well reported, though still not universally accepted, that many
GPCRs appear to form homo- and hetero-dimers. The research em-
phasis now has shifted to the structural characteristics and functional
signiﬁcance of oligomeric states. Several roles for dimerization have
been suggested but there are no consistent commonalities amongst
families [15,16]. Conventionally, it is thought that one receptor
sub-unit promotes GDP-GTP exchange on one G-protein. However,
it has been proposed that one receptor molecule may not be sterically
able to provide simultaneous interaction with all the G-protein
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trans-activation between subunits in a complex and the potential
for discrete signaling pathways [18,19].
Several TM domain interfaces have been predicted for Family A
receptors, including TM4 and TM5 in rhodopsin [20,21] and in the
D2 dopamine receptor [22–25]. Further to this, by employing a
bioinformatics and molecular modeling approach to current available
data, Simpson et al., have implicated TM4 to have a key role in
dimerization across family A GPCR's [26]. Cysteine mutagenesis and
cross-linking studies with the D2 dopamine receptor have discrimi-
nated between the “active” R* state (agonist bound) conformation
[24] represented by a TM4 only interface and the “inactive” R state
(inverse agonist bound) conformation, demonstrating TM4 and pos-
sible TM5 involvement [20,21]. In rhodopsin, through disulphide
bond formation at helix 8, Cys316 was implicated as a contact site
in the homo-dimer [27]. Recent crystal structure of the dimeric
μ-opioid receptor bound to the antagonist morpinan, has shown
TM6-TM5 and TM1-TM2-H8 as potential interface regions [28].
Finally, a recent exploration of ligand bias has re-examined the possi-
bility of oligomerization and multiple conformation involvement in
G-protein directed signaling [18].
There is evidence from enzyme linked immunosorbent assays and
ﬂuorescence energy transfer studies [29] to suggest that MC4R assem-
bles as a homo-dimer, but the sites of interaction and the functional sig-
niﬁcance are slightly understood [29,30]. Additionally, binding kinetics
for the agonist, NDP-MSH, has suggested a tandemly-arranged binding
site across the homo-dimer [31,32]. Dominant negative mutations of
the MC4R including D90N and S136P have been used to model interac-
tion between dimers that stabilize the TM helical arrangement. These
data suggest that TM2, TM3 and TM7 are important in the dimeric com-
plex [33] and raise the possibility ofmulti-activated states and differen-
tial G-protein coupling which result in biased agonistic action [34].
Here, we characterize the oligomeric form of theMC4R, including the
identiﬁcation of one of its contact sites, the presence of higher order
oligomeric species and the novel involvement of the G-protein in confor-
mational rearrangements. We have also explored co-operative behavior
between the receptor and the G-protein and between individual protein
subunits.
2. Materials and methods
2.1. Materials
The expression vector, pcDNA3, containing cDNA for the human
wild type (WT)-MC4R was provided by Dr. Sharon C. Cheetham (BASF
Pharma, Nottingham). The pcDNA3.1 Hygromycin© vector was pur-
chased from Invitrogen (Paisley, UK). [125I] NDP-MSH and [125I]
SHU9119 were obtained from Perkin Elmer Life Sciences (Boston, MA,
USA). Non-radioactive peptides were purchased from Bachem (St.
Helens, UK), cell culture reagents from Invitrogen (Paisley, UK) and pro-
tease inhibitor cocktail tablets from Roche (Lewes.UK). Oligonucleotide
primers were synthesized by Sigma-Genosys Ltd. (Pamisford, UK).
2.2. Amino-terminal tagging
The HA (YPYDVPDYA) and c-Myc (EQKLISERDL) N-terminally
tagged WT-MC4R was generated using the polymerase chain reaction
(PCR). The sequence contained a Hind III restriction site. A BamH I
restriction site was incorporated into the 3′-carboxyl terminus primer
at the stop codon. The constructs were sub-cloned into pcDNA3 vector
and pcDNA3.1 Hygromycin©.
2.3. Mutagenesis
Point mutationswere introduced into theWT-MC4R sequence using
the QuikChange® Site-Directed Mutagenesis Kit (Stratagene) with theMC4R-pcDNA3 vector and c-Myc-MC4R-pcDNA3.1 Hygromycin© as
template.
2.4. HEK-293 cell transfection
HEK-293 cells were passaged 24 h prior to transfection, and seeded
at 70% conﬂuency. On the day of transfection, 6.5 μg/ml of DNA was
added to serum-free DMEM with 2% of Plus reagent (Invitrogen) and
1.25% of Lipofectamine™ (Invitrogen) according to the manufacturer's
instructions. The reaction was terminated by the replacement of the
media with complete DMEM. Two days after transfection, cells were
harvested using 0.02% EDTA in PBS, and pelleted by centrifugation at
4000 rpm for 5 min (Hettich, Rotoﬁx 32, swingout rotor). The cell
pellets were washed twice with PBS (Dulbecco's) and re-suspended in
an appropriate solution according to the investigation to be carried
out. Alternatively, cells were harvested for propagation of stable
transformants in the appropriate selection media, depending on single
or dual transfection. If dual transfection occurred, both pcDNA3 and
pcDNA3.1 Hygromycin© were utilized simultaneously during DNA/
Lipofectamine™ complex formation.
2.5. Cell growth
HEK-293 cells were routinely maintained in DMEM medium
supplemented with 10% fetal calf serum, 100 μg/ml penicillin,
100 μg/ml streptomycin and Glutamax™ (Invitrogen). Stably transfected
cells were grown in the same medium supplemented with 800 μg/ml
Geneticin G418 sulfate or/and 200 μg/ml Hygromycin. Cells were grown
at 37 °C in 5% CO2.
2.6. Membrane preparation
Cell membranes were prepared from cells grown as a monolayer to
conﬂuency. The growth medium was removed and the cells were
washed three times with 10 ml cold PBS. The cells were then treated
with 0.02% EDTA solution for 15 min, harvested, and centrifuged at
5000 rpm for 5 min. The cell pellet was re-suspended in assay buffer
(25 mM HEPES-KOH, 1.5 mM CaCl2 1 mM MgSO4 100 mM NaCl, and
pH 7.0 plus protease inhibitors), and homogenized using a teﬂon/glass
homogenizer. The homogenate was then centrifuged for 10 min at
31000 rpm, at 4 °C. The supernatant was discarded and the pellet was
re-homogenized in assay buffer and centrifuged as before. Finally, the su-
pernatant discarded the pellets homogenized in 25 mM HEPES-KOH
(pH 7.0), containing 10% sucrose and the membranes frozen at−70 °C.
2.7. Cross-linking
Membranes (50 μg of protein) were diluted to a concentration of
25 μg/ml with binding buffer (25 mM HEPES-KOH, 1.5 mM CaCl2,
1 mM MgSO4, 100 mM NaCl, and pH 7.0 plus protease inhibitors).
Cross-linking was induced using 5 mM copper 1–10 phenanthroline
(CuP) at 22 °C for 1 h. The reaction was terminated by addition of 5
times SDS sample buffer (60 mM Tris–HCl, pH 6.8, 2% SDS, and 10%
glycerol) containing 25 mM N-ethyl maleimide (NEM) to react with
any free sulfhydryl groups.
2.8. Co-immuno-puriﬁcation
1000 μg of CuP treated membranes expressing HA- and c-Myc
tagged WT-MC4R were incubated with 3:1 ratio of immuno-
puriﬁcation buffer (25 mM HEPES-KOH, 1.5 mM CaCl2, 1 mM MgSO4,
100 mM NaCl, 1% Triton-X, and pH 7.0 plus protease inhibitors).
100 μl of Anti-c-Myc protein G-conjugated beads was added overnight
at 22 °C, after which, the beads were washed with 0.5 ml of immuno-
puriﬁcation buffer, and centrifuged (12,000 g) for 2 min. The superna-
tant was discarded and the wash step was repeated 10 times. Finally
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sample buffer (62.5 mM Tris/HCl pH 6.8, 2% SDS, 5% sucrose and
0.009% bromo blue) without β-mercaptoethanol, for 30 min at 37 °C.
The samples were centrifuged and the supernatants were collected.
This was repeated twice and the supernatants were pooled. The
samples were resolved by 12.5% SDS-PAGE, and Western blotting was
carried out with antibodies to the HA epitope.2.9. Immunoblotting
Proteins were resolved on a 12.5% SDS-PAGE gel and electroblotted
on to polyvinylidinediﬂuoride (PVDF) membranes (Fluoro Transr). The
membrane was blocked for 1 h at room temperature with Super Block
in PBS (Roche Molecular Biochemicals). The MC4R was identiﬁed
using anti-HA-HRP (Sigma) to the N-terminal tag at a dilution of
1:1000, and antibody AB5134 (Chemicon international) was raised to
the rat MC4R at a 1:1000 dilution in antibody buffer (PBS plus 10%
BSA). Immuno-reactivity was determined with anti-rabbit horseradish
peroxidase-conjugated antibody (Amersham Bioscience) in antibody
dilution buffer (1:5000) by Chemiluminescence (Roche Molecular
Biochemicals).2.10. Radio-ligand binding assays
Homologous competition binding assays were performed by incu-
bating membranes (5–50 μg) in binding buffer, in triplicate with
(40,000–60,000 cpm) 0.2 nM of [125I] NDP-MSH or [125I] SHU9119
(2000–6000 cpm counts for total binding respectively). Several
known concentrations of equivalent ligand were allowed to compete
for the radio-ligand in a volume of 100 μl. The mixture was incubated
for 45 min at room temperature. The reaction was stopped by ﬁltra-
tion through 0.5% polyethyleneimine and 1 mg/ml BSA pre-treated
ﬁlters and washed with 200 μl ice-cold PBS. Non-speciﬁc binding
was measured using 1 μM SHU9119.2.11. Cyclic AMP response (CRE)-luciferase assay
24 h post-transfection, HEK-293 CRE-luc cells were plated into 96
well blackwall, clear bottom, and poly-D-lysine coated microplates
(Corning Costar) at a density of 50,000 cells/well and cultured for a
further 12–18 h. Media were replaced with 100 μl phenol-red-free
culture medium including IBMX and the appropriate concentration
of agonist NDP-MSH. [35]. The microtitre plates were incubated for
4 h at 37 °C after which Luclite® reagent (Perkin Elmer) was added
to each well, the plates were sealed and subjected to dark adaptation
for 5 min at room temperature. Luciferase activity was determined by
luminescence using NOVAstar (BMG).Fig. 1. Immuno-precipitation of the human WT-MC4R oligomer in the presence and
absence of the Gα-protein. The human WT-MC4R was tagged with either the HA or the
c-Myc epitope at the N-terminus. Both forms were stably expressed together in
HEK-293 cells (lanes 1, and 4 and 5). Immuno-puriﬁcation was performed on the dual
expressedmembranes using anti-c-Myc conjugated Protein A beads. The puriﬁed proteins
were resolved on SDS-PAGE and subjected toWestern blottingwith anti-HA-HRP to iden-
tify the co-purifyingHA-WT-MC4R (36 kDa) thatwas indicative of homo-dimer formation
between c-Myc-WT-MC4R and HA-WT-MC4R (lanes 1, 4 and 5). Addition of 1 mMGTPγS
(plus agonist) to uncouple the Gα-protein did not affect dimer formation (lane 5).2.12. Data analysis
All measurements, except where stated otherwise, were carried
out in triplicate in three independent experiments. The values quoted
and depicted graphically are the means of the independent determi-
nations with the corresponding SEM. In competition binding studies,
counts were normalized to the maximum and non-speciﬁc binding
within each data set and the pIC50 values were calculated with a sin-
gle site-binding model, ﬁtted with the aid of GraphPad PRISM 3.0
software (San Diego, CA). The pKd values were obtained from the
IC50 using the following equation Kd= IC50− [radio-ligand] [36] and
pKd=− log[Kd]. In homologous binding assays, Bmax values were
determined using Bmax=B0*IC50*[L−1] [37]. The signiﬁcance of differ-
ences between values was determined by comparing mean values
using two tailed unpaired or paired Student's t test.3. Results
3.1. Identiﬁcation of a wild type MC4R homodimer
Membranes prepared from HEK-293 cells stably transfected with
both HA and c-Myc tagged forms of the cloned human WT-MC4R, were
isolated, solubilized in mild detergent and subjected to immuno-
puriﬁcation using immobilized anti-c-Myc antibody. The bead-retained
fraction was solubilized with SDS and subjected to PAGE, followed by
Western blotting using an anti-HA antibody. This revealed a clear band
migrating with a mass equivalent to 36 kDa (Fig. 1), identical to that
seen using antibody to the wild-type receptor or to the c-Myc tag. The
same result was obtained when membranes were incubated with
1 mM GTPγS (binds irreversibly to the G-protein, uncoupling it from
the receptor) plus 0.5 mM NDP-MSH prior to solubilization and
immuno-puriﬁcation (Fig. 1). This suggests that MC4R is a stable dimer,
in the plasma membrane with and without the G-protein or the ligand.
Solubilization and mixing of membranes from cell-lines expressing
either HA-WT-MC4R or c-Myc-WT-MC4R, prior to immuno-puriﬁcation
and Western blotting as above, demonstrated that no aggregation of
the HA- with the c-Myc-tagged protein occurred during solubilization
and incubation (Fig. 1), reinforcing the formation of stable dimers in
the intact cell.
Further controls included immuno-puriﬁcation of the dimeric formof
the receptor under different detergent conditions (n-dodecyl-beta-
D-maltoside and n-octylglucoside) to exclude any possibility of receptor
co-location in triton-resistant lipid domains.
Homologous binding studies using either the agonist [125I] NDP-MSH
or antagonist [125I] SHU9119 with cell lines stably expressing either the
tagged or untagged WT-MC4R indicated that addition of the tags had no
effect on the functional properties of the receptor (Table 1).
3.2. Cross-linking the dimeric MC4R complex
Membranes prepared from HEK-293 cells stably expressing the
WT-MC4R were incubated for 1 h at room temperature without and
with 5 mM CuP (Fig. 2), washed, solubilized in mild detergent and
subjected to SDS-PAGE under reducing and non-reducing conditions.
Subsequent Western blotting with a polyclonal antibody to the MC4R
Table 1
Antagonist and agonist binding properties of the MC4 receptor. Homologous competition binding studies were performed using [125I] labeled and unlabeled forms of SHU9119 or
NDP-MSH. The number of independent experiments is shown in brackets. Data are expressed as pKd±S.E.M. or Bmax±S.E.M. (fmol/mg of protein). Signiﬁcant differences were
evaluated using the student t test and comparisons made between WT-MC4R vs WT-MC4R plus GTPγS, or c-Myc-WT-MC4R vs c-Myc-C84A-MC4R for both [125I] NDP-MSH and
[125I] SHU9119 binding. WT = Wild type, HA and c-Myc are the tagged versions and C84A a mutant. N/A indicates no activation, * indicates pb0.05 using Student t test.
MC4R mutation/assay condition [125I] SHU9119 binding [125I] NDP-MSH binding
pKd Bmax (fmol/mg of protein) pKd (nM) Bmax (fmol/mg of protein)
WT 8.32±0.01 (3) 1452±384 (3) 7.98±0.01 (8) 746.0±43.0 (8)
WT(1 mM GTPγS) 8.21±0.27 (7) 1725±90.0 (7) 7.44±0.11 (8) 3532±688* (8)
c-Myc-WT 8.60±0.10 (3) 1699±277 (3) 7.53±0.23 (3) 1234±241 (3)
HA- and c-Myc-WT N/A N/A 7.64±0.16 (3) 475.0±34.0 (3)
c-Myc-C84A 8.54±0.28 (3) 1001±145 7.25±0.24 (2) 843.0±33.0 (3)
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ed with CuP and run under non-reducing conditions. In the absence of
CuP only the 36 kDa monomeric receptor is seen (the 40 kDa species
is non-speciﬁc labeling seen also in the non-transfected cells). The olig-
omer dissociated under reducing condition conﬁrming the formation of
a disulphide bond. Disulphide bond formation occurred in a time-
dependent manner and was essentially complete within 30 min with
5 mM CuP at 4 °C.
3.3. Identiﬁcation of residues involved in cross-linking
There are 15 Cys residues in MC4R. Site-directed mutagenesis was
used to introduce single Ala mutations at all these positions (Table 2).
A double mutant (C318A, C319A) was also produced. All the mutants
except C84A-MC4R retained the ability to form a disulphide bond
(Fig. 3). Cys84 resides near the cytoplasmic surface of TM2. No
cross-linking was observed on treatment of whole cells with CuP
conﬁrming that this residue is only responsive to oxidizing conditions
in membrane preparations.
The afﬁnity of the agonist for c-Myc-C84A-MC4R in a stable HEK-293
cell line (pKd=7.25±0.24) was the same (*pb0.05, unpaired t test) as
that of c-Myc-WT-MC4R in stable HEK-293 cell line (pKd=7.53±0.23).
Full characterization of the mutants with Cys residues predicted to be
located in the binding pocket is found in Cox et al. (2006).
3.4. Conformation of the cross-linked homodimer and identiﬁcation of
higher order oligomers
Further co-immuno-puriﬁcation studies were carried out using
membranes from cells expressing both c-Myc-WT-MC4R and HA-WT-
MC4R. Following treatment with 5 mM CuP, the dimeric species atFig. 2.Western blotting of cross-linked human WT-MC4R. (Panel A) Membrane samples pre
copper 1–10 phenanthroline (CuP) for 1 h at room temperature. The samples were resolved
the MC4R. Untreated membranes revealed the monomeric MC4R, with a MW of 36 kDa (lane
(lane 3), via a covalent bond, which was reduced by the addition of βME (lane 4). Untreated
2). (Panel B) It demonstrates that the band at 40 kDa is present when HEK-293 cells are not
at 4 independent occasions. Molecular mass is indicated as kDa.70 kDa can be conﬁrmed as a homo-meric complex, purifying with
anti-c-Myc and blotting with anti-HA (Fig. 4).
When similar immuno-puriﬁcation studies were performed on
membranes expressing HA-WT-MC4R with c-Myc-C84A-MC4R and
subjected to CuP treatment, followed by SDS-PAGE in the absence of re-
ducing agent, the covalent dimeric bandwas seen following puriﬁcation
via the c-Myc epitope and blotting with the anti-HA antibody (Fig. 4).
Since the C84A mutant cannot form covalent dimers (Fig. 3), this im-
plies that cross-linked complex is the HA-WT-MC4R and must have be-
come associated in-situ with the c-Myc-C84A-MC4R mutant to enable
co-immuno-puriﬁcation with the anti-cMyc antibody, thereby provid-
ing evidence for higher order oligomerization.
When immuno-puriﬁcation via the c-Myc epitope was performed
with both the c-Myc-WT-MC4R/HA-WT-MC4R and c-Myc-C84A-
MC4R/HA-WT-MC4R dual expressed membranes in the absence of
CuP, the 36 kDa band blotted with the anti-HA antibody in both cases,
indicative of a stable complex in mild detergent.
3.5. The signiﬁcance of uncoupling the G-protein
The nucleotide GTPγS is known to bind to the Gα sub-unit,
uncoupling the G-protein from the receptor [38]. Membranes were in-
cubated at room temperature for 30 minwith GTPγS at various concen-
trations from 100 nM to 1 mM in the presence of 0.5 mM NDP-MSH.
Western blot analysis (Fig. 5) indicated that 1 mM GTPγS after
30 min completely prevented covalent dimerization on subsequent
treatment with CuP.
Immuno-puriﬁcation studies with membranes treated with 1 mM
of GTPγS, demonstrated that although the receptor could no longer be
covalently cross-linked, the dimer still existed (Fig. 1). The Gαs-protein
puriﬁeswith the dimeric form of the receptor but not in the presence ofpared from HEK-293 cells expressing the human WT-MC4R were incubated with 5 mM
on 12.5% SDS-PAGE, and detected using a polyclonal antibody (Chemicon AB5134) to
1) and a non-speciﬁc band at 45 kDa. Incubation with CuP caused the MC4R to dimerise
membranes were also subjected to βME to reduce any internal disulphide bonds (lane
transfected with MC4R, and therefore is non-speciﬁc. The experiment was repeated on
Table 2
Table of all 15 Cys residues located on the MC4R.
Cys residue on receptor Position
40 N-terminus
84 TM2
130 TM3
138 TM3
172 TM4
177 TM4
196 TM5
256 TM6
271 ECLIII
277 ECLIII
279 ECLIII
293 TM7
318 C-terminus
319 C-terminus
326 C-terminus
Fig. 4. Identiﬁcation of higher order oligomers of theMC4 receptor. Versions of the human
WT-MC4R containing either an HA or a c-Myc epitope on the N-terminus were stably
expressed together in the same cells. Membranes isolated from this cell line were treated
with and without CuP for 1 h at room temperature. After immuno-puriﬁcation using the
c-Myc epitope, the protein was subjected to SDS-PAGE followed by Western blotting with
anti-HA-HRP antibody. In the absence of CuP (lane 1), a band was detected at 36 kDa (as
seen in Fig. 1), depicting subunits from the homo oligomer. In the presence of CuP (lane
3), a band was detected at 70 kDa representing a cross-linked species between c-Myc-
WT-MC4R and the HA-WT-MC4R. This experiment was repeated with membranes stably
expressing HA-WT-MC4R and c-Myc-C84A-MC4R. A dimeric species was seen with mem-
branes incubated with CuP (lane 4) but only the monomer in the absence of CuP (lane 2)
Cys84 has been shown to be responsible for CuP induced crosslink, suggesting that high
order oligomers were occurring. Experiments were repeated in triplicate. Molecular mass
is denoted in kDa.
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the MC4R is reduced dose dependently with GTPγS (Fig. 6). The two
condition-covalent crosslinking and G-protein association are inversely
correlated and presumably reﬂect a subtle conformational difference,
affecting this region of the receptor.
In further studies to examine the concentration-dependent effect of
GTPγS on Gαs coupling, membranes (expressing both HA-WT-MC4R
and cMyc-WT-MC4R) were treated with increasing concentration of
GTPγS (1 μM–1 mM) for 30 min and the receptor immuno-puriﬁed
using the c-Myc epitope. Western blotting of Gαs and the HA epitope
of the MC4R, demonstrated a concentration-dependent decrease in Gα
association with the MC4R in the presence of 1 μM to 1 mM GTPγS,
but there was no change in the levels of the MC4R on immuno-
puriﬁcation (Fig. 6).
Analysis of the afﬁnity of the receptor for both the agonist and antag-
onist in the presence of 1 mM GTPγS indicated that the pKd for
SHU9119 was unaltered (8.32 vs. 8.21, without and with 1 mM GTPγS
respectively) (Fig. 7a), while the pKd for the agonist was shifted slightly
to the right, (7.98±0.01 to 7.44±0.11 for NDP-MSH without and with
1 mMGTPγS respectively). This is validated by historic datawhere only
a 3-fold change in the Kd occurred in the presence of 30 μM GTPγS
[6,39].
Further experiments were carried out at increasing concentrations
of GTPγS with 0.2 nM [125I] NDP-MSH (Fig. 7b) or [125I] SHU9119. At
high concentrations of GTPγS, speciﬁc binding of both ligands in-
creased (Fig. 7b). From 1 μM to 1 mM GTPγS, the percentage
speciﬁc-binding roughly doubled for the agonist. Interestingly, this
increase correlated with inhibition of cross-linking of the receptor
in the presence of GTPγS as assessed by Western blotting and densi-
tometry. The pEC50 for GTPγS on NDP-MSH binding was 4.22±
0.21 μM, which is not signiﬁcantly different (*pb0.05, paired t test)
to the effect on the percentage cross-linking inhibition (increase of
monomer formation), which was 4.14±0.23.Fig. 3. Identiﬁcation of the Cys residue responsible for cross-linking the wild type MC4R in th
HEK-293 cells. Membranes were prepared for each mutant and treated with and without 5 m
using the antibody to the MC4R (Chemicon). Molecular mass is denoted in kDa. The mutant
occasions.Additionally, the Bmax values calculated from competition curves
without and with 1 mM GTPγS for NDP-MSH were 746±43 fmol/mg
and 3532±688 fmol/mg*, respectively and for SHU9119 1452±
384 fmol/mg and 1725±89.8 fmol/mg, respectively. The Bmax for the
agonist NDP-MSH, increased signiﬁcantly ~4 fold (*pb0.05, unpaired t
test), which is similar to the increase in speciﬁc binding of NDP-MSH
in the presence of the equivalent concentration of GTPγS (Fig. 7b).
Other nucleotides used in the same concentrations also induced an ef-
fect on the level of Bmax, for example Gpp(NH)p by a similar level to
GTPγS, GTP to a lesser extent, and ATP and GDP less still.
3.6. Trans-activation within the MC4R oligomeric complex
In order to examine the possibility of trans-activation, a series of ex-
periments were carried out utilizing receptors lacking either the ability
to activate or to interact with the agonist NDP-MSH. The ﬁrst receptor
characterized was c-Myc-C318A-MC4R, bearing a mutation at a poten-
tial palmitoylation site located on the C-terminal region of the receptor.
This mutant is interesting because it cannot be activated (Table 3) but
the binding afﬁnity of this receptor for the agonist NDP-MSH was only
slightly shifted to the right by approximately ~3.5-fold compared to
the c-Myc-WT-MC4R (pKd=7.05±0.35 vs 7.60±0.19) while the pKd
for the antagonist SHU9119 was unaltered. This proﬁle is reminiscent
to the uncoupled state of the WT-MC4R (Table 1). The second groups
of receptors lack completely or have a signiﬁcant reduction in theire presence of CuP. Cys residues were mutated in turn to alanine, and stably expressed in
M copper1-10-phenanthroline (CuP) at 22 °C for 1 h. Western blotting was performed
c-Myc-C84A-MC4R did not form a disulphide bond. The experiment was repeated on 3
Fig. 5. Western blotting of the cross-linked MC4R dimer after pre-treatment with GTPγS.
Membrane samples prepared from HEK-293 cells expressing the human WT-MC4R were
incubated with 1 mM, 100 μM, 10 μM, and 100 nM of GTPγS (lanes 4–7 respectively) in
the presence of 0.5 mM NDP-MSH for 30 min. The samples were then treated with
5 mM copper-1-10 phenanthroline (CuP) prior to SDS-PAGE. Western blotting with the
polyclonal antibody to the MC4R (Chemicon AB5134) revealed monomeric MC4R
(36 kDa) (lanes 1and 3) and dimeric MC4R (70 kDa) in the presence of CuP alone (lane
2) and CuP plus NDPMSH (lane 4). Pre-treatment of membranes with GTPγS inhibited
the formation of the dimeric complex. The experiment was repeated on three separate
occasions.
540 K.L. Chapman, J.B.C. Findlay / Biochimica et Biophysica Acta 1828 (2013) 535–542ability to bind the agonist. They include themutations D126C andM292C
(binding not detected in competition studies). NDP-MSH potency was
also signiﬁcantly reduced (D126C; pEC50=4.57±0.05, M292C; pEC50 =
No activation). When the mutant c-Myc-C318-MC4R was transiently
expressed in HEK-293 cell lines stably expressing the D126C-MC4R mu-
tant, the pEC50 for NDP-MSH was measured as 8.30±0.07 similar to WT
potency. Similarly, when c-Myc-C318-MC4R was transiently expressed
in M292C-MC4R HEK-293 cell lines, most of the WT-MC4R NDP-MSH
like activation was dramatically restored (pEC50=6.72±0.29). Ligand
binding by membranes from cells expressing the D126C/C318A and
M292C/C318A combinations was not signiﬁcantly different from C318A/
WT membranes (pKd=7.52±0.07, 7.54±0.04 and 7.53±0.12 respec-
tively), illustrating that the dysfunctional-binding receptors were not
perturbing the ligand binding characteristics of the C318 mutant. What-
ever the detailed molecular mechanism of this effect, it is clear that
cross-talk occurs between the two-receptormonomerswhich have effec-
tively retained their ability to assume the R* state.
4. Discussion
The work presented here, shown through Western blotting,
immuno-puriﬁcation, cross-linking techniques and agonist activity stud-
ies, demonstrates the existence of an MC4R homo-dimer in cells stably
expressing the receptor. Homo-dimer formation is consistent withFig. 6. The effect of GTPγS on G-protein coupling to the human WT- MC4R. (Panel A)
Membrane samples prepared from dual expressed HA and c-Myc-WT-MC4R HEK-293
cells were incubated with 0.001 mM–1 mM of GTPγS for 30 min. The samples were
then solubilized and immuno-puriﬁed using the c-Myc epitope. The G-protein was
detected using a polyclonal antibody against Gαs (Santa Cruz, Sc-823). (Panel B) The
HA-MC4R was detected using an antibody to the HA epitope (Sigma) from the IP samples
to standardize for protein levels.sandwich enzyme-linked immunosorbent assays and ﬂuorescence ener-
gy transfer studies [29,30]. The dimer can be covalently cross-linked
thoughdisulphide bond formation under oxidizing conditions.Mutagen-
esis studies indicate that only the wild type residue Cys84, in near prox-
imity to the cytoplasmic surface of TM2, undergoes cross-linking. The
implication of this is that the homo-dimer has an interface in or very
near TM2, albeit that Cys84 may not be intimately critical to the interac-
tion since mutation to alanine does not perturb dimer formation. How-
ever, the two cysteine residues are sufﬁciently close that cross-links
form in an oxidizing environment without the intervention of a
cross-bridge. The \S\S-cross-linked form of the WT-MC4R immuno-
puriﬁedwith the C84A-MC4R variant suggesting that an oligomeric com-
plex was formed between the WT-MC4R dimer and the C84A-MC4R
mutant. It is most unlikely that theWT-MC4Rwould cross-link preferen-
tially with another\SH on the C84A-MC4R since this would imply con-
siderable conformational re-arrangements in a dimer species, which is
very stable even when the Cys84 residues are replaced with an alanine.
Moreover, we detected no evidence that there was any change in the
functional characteristics of the mixed species or any cross-linking with
the C84A mutant alone as might be expected if conformational changes
were occurring. Therefore, the data suggest these dimers can also form
higher order oligomers, presumably involving a different interface such
as those identiﬁed in other GPCR dimeric complexes. In the case of rho-
dopsin and the D2 dopamine receptor, the dimer interface is thought to
be located on TM4 [21,24–26] or H8 [27], however a recent crystal struc-
ture of the opioid receptor has elucidated that TM5–TM6 is important
[28].
Both the WT-MC4R and the TM2 mutant C84A-MC4R were active
and capable of interaction with the G-protein (Fig. 5); illustrated
through co-immuno-puriﬁcation studies. However, cross-linking
through this Cysteine residue was completely abolished by incubation
with 1 mM GTPγS (agonist stimulated) at room temperature (and in
a dose dependent manner), which uncoupled the Gα-protein from
the receptor in a similar dose effect (Fig. 7). However, when the
receptor is devoid of the G-protein, it still remains oligomeric as demon-
strated through Co-IP (Fig. 1). This indicates that the receptor is a con-
stitutive dimer, but the conformation of the interaction site (and
potentially of other regions in the whole protein) alters when coupled
with the G-protein. It is not yet clear if this dynamic process involves
changes in higher levels of oligomerization but the functional conse-
quences are related to the occupancy of the oligomeric complex.
In the coupled form (G-protein associated), MC4R exists as a dimer
(TM2:TM2). When in the uncoupled state, the receptor remains a
dimer (with a somewhat lower afﬁnity for the agonist but not the an-
tagonist). Using two methods of quantifying occupancy (competition
binding [125I] NDP-MSH binding in the presence and absence of
NDP-MSH to elucidate Bmax or total binding of [125I] NDP-MSH when
GTPγS is titrated), it is clear that when the receptor is in an uncoupled
state, the Bmax values are increased compared to the coupled state.
This suggests that when in the G-protein coupled form, the receptor ap-
pears to exhibit behavior akin to negative co-operativity. Perhaps the
agonist binds to only one of themonomers with high afﬁnity. Kopachuk
and colleges, through kinetic studies, have suggested that MC4R binds
NDP-MSH with two tandemly arranged, interconnected, mutually de-
pendent binding sites [31,32]. Additionally, only one of the NDP-MSH
units dissociates from the dimer; the other has a very slow off rate.
Herewe have shown thatMC4R, when in the G-protein bound state, ex-
hibits occupancy for NDP-MSH lower than when unbound.
Western blotting demonstrated that the level of G-protein association
with the receptor corresponds to the levels of binding and cross-linking.
Additionally, the same concentrations of other nucleotides, including
GTP, GDP and ATP bring about a similar, though less pronounced effect
as GTPγS, implying a clear G-protein-mediated effect. It is possible that
the G-protein is rather tightly associated with the receptor in the endog-
enous situation and that the coupled and uncoupled conformations have
similar afﬁnity values. Negative co-operativity between theG-protein and
Fig. 7. The effect of GTPγS on agonist and antagonist binding and on the cross-linked conformation of theMC4R. (Panel A)Homologous competition analysis ofWT-MC4R treatedwith and
without 1 mMGTPγS. [125I] NDP-MSH (0.2 nM; upper) and [125I] SHU9119 (lower) bindingwas competedwith the unlabeled homologous ligand. The data are representative of at least 3
independent experiments performed in triplicate and analyzed in triplicate. (Panel B) Competition studies of [125I] NDP-MSH binding using increasing concentrations of GTPγS (■); left
axis.Westernblot densitometry of the percentage cross-linking inhibited by increasing concentrations ofGTPγS, is shownby (○) taken fromFig. 6; right axis. The EC50 values for GTPγS on
[125I] NDP-MSH binding, and percentage inhibition of cross-linking were 4.22±0.21 μM and 4.12±0.23 μM respectively. (pb0.05, paired t test, n=4).
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the dimer changes conformation to the uncoupled state (as demonstrated
by the cross-linking results), the Bmax values for both the agonist and the
antagonist increase. Whether this is as simple as negative co-operativity
within the dimeric complex or related to a more extended oligomeric
array will require further pharmacological investigation.
The native, non-activated state of the receptor is in a conformation
that facilitates cross-link formation. When activated, the resulting
conformation state (associated with uncoupling) is not able to
cross-link, presumably due to an altered positioning of Cys84. Thus,
it appears that the MC4R protein is in a dynamic and sensitive state
as illustrated by its structural and functional characteristics and by
the presence of both a native agonist and inverse agonist.
Our studies show that mutation of C318A, located in the C-terminal
region, resulted in a loss of the ability to increase cAMP production,
but the binding of the agonist as assessed using competition studies
was unaffected. Themutant receptors D126C andM292C showed no de-
tectable binding using competition studies and NDP-MSH potency wasTable 3
MC4 receptor trans-activation. HEK293 cells were stably expressed with the single form of M
siently transfected with the mutant C318A MC4R. Membranes were prepared for ligand bin
agonist [125I] NDP-MSH. Data are expressed as pKd±S.E.M. HEK293 cells with CRE-Luc g
CRE-luciferase assays were used to identify receptor activity. Data are expressed as pEC50±
ences were evaluated using the Student t test, and comparisons were made between single
mutant (§pb0.05). NA = no activation. NB = no binding.
MC4R expression in HEK-293 cell [125I] NDP-MSH binding
pKd
WT 7.60±0.19 (3)
C318A 7.05±0.35 (3)
D126C NB
M292C NB
D126C/C318A 7.52±0.07 (3)
M292C/C318A 7.54±0.04 (3)
WT/C318A 7.53±0.12 (3)signiﬁcantly reduced or abolished altogether. When the C318A mutant
was co-expressedwith theMC4Rmutants D126C orM292C, near normal
levels of activation were restored. Neither complex caused any signiﬁ-
cant change in Kd for agonist compared to the C318A mutant alone. It
is plausible that the mutation C318A affects G-protein interaction with
the receptor rather than changing the active conformation of the recep-
tor so that D126C allows full activation.
Accumulating data have suggested that receptors form at least di-
mers [40] and that there can be a level of co-operativitywithin the com-
plex. Again, only one site of action has been assumed in the allosteric
modulation by the G-protein of the R* state [41]. However, the possibil-
ity ofmore than one-or-more different sites of interaction should not be
ignored. A series of competition experiments and saturation curves
have introduced a role for co-operativity,with ligand binding oscillating
between two states of cross-talk [42]. Co-operativitywas terminated by
dissociation of one of the proteins or independent binding of ligand by
the receptor. However, this model may over-simplify the system as it
does not take into account different interactions between the receptorC4R (WT- or C318A- or D126C- or M292C-MC4R). These stable cell lines were then tran-
ding experiments. Homologous competition binding studies were performed using the
ene were then transiently transfected with either single or dual forms of the MC4R.
SEM. The number of independent experiments is shown in brackets. Signiﬁcant differ-
and dual expressed membranes (*pb0.05) and WT-MC4R vs WT-MC4R expressed with
CRE-Luc cAMP activity assay
Bmax (fmol/mg protein) pEC50
1234±241 (3) 8.27±0.27 (3)
1052±37.1 (3) NA (3)
4.57±0.05§ (3)
NA (3)
3050±344 (3) 8.30±0.07* (6)
3320±475 (3) 6.72±0.29*§ (6)
2708±261 (3) –
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type of G-protein [43]. There is also the possibility of domain swapping
as postulated previously [44–46] but this seems less likely since these
are essentially the same monomers varying only in a single mutation
in quite different regions of themolecule. However the recent emerging
documentation of biased ligand signaling through multi-state receptor
conformations [44,45], may provide insights into the different levels
of occupancy for the agonist with regards to the dimeric conformation.
5. Conclusion
The data presented here demonstrate that the MC4R forms a con-
stitutive dimer (and possibly even a higher order complex) which ex-
ists in different conformations depending on association with the
G-protein and the agonist i.e. the oligomeric state is both stable and
conformationally dynamic. At least one interaction is made between
the receptor sub-units; this allows disulphide cross-linking at the
cytoplasmic surface of TM2 under oxidizing conditions. This interface
reﬂects the G-protein coupled state, and the dimeric species. This
state appears to regulate the ligand occupancy of the receptor. Fur-
ther studies indicate that there is cross-talk between the monomers
such that binding of a single ligand to one monomer can induce the
active state in the other. There are, therefore, high levels of modula-
tion not only between two receptor sub-units in a dimeric complex
but also between the G-protein and the receptor.
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